Recent Press Releases

"Real World" Data Support Use of Blood Test for EGFR Mutation in Advanced NSCLC

GENEVA, April 17, 2015 /PRNewswire/ --

CheckMate -057, a Pivotal Phase III Opdivo (nivolumab) Lung Cancer Trial, Stopped Early

Opdivo Demonstrates Superior Overall Survival Compared to Docetaxel in Patients with Previously-Treated Non-Squamous Non-Small Cell Lung Cancer Friday, April 17, 2015 RINCETON, N.J.--Bristol-Myers...

Annual General Meeting Approves Dividend Increase

Executive Board actions approved by a significant majority Darmstadt, Germany, April 17, 2015 – At the Annual General Meeting of Merck held in Frankfurt am Main today, shareholders approved...

Merck Proposes Dividend Increase to AGM After a Year of Key Strategic Moves – Foundation Set for Further Organic Growth

Major highlights of 2014 include offer for Sigma-Aldrich, alliance with Pfizer and integration of AZ Electronic Materials  Merck proposes a dividend increase of € 0.05 to € 1.00 Darmstadt,...

Amgen Announces Webcast Of 2015 First Quarter Financial Results

THOUSAND OAKS, Calif., April 16, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that it will

Sandoz receives FDA approval for GlatopaTM as the first generic competitor to MS therapy Copaxone® 20mg

Glatopa is the first FDA-approved, substitutable generic version of Copaxone® 20mg, a treatment for relapsing forms of multiple sclerosis Novartis and Sandoz are driving access to a full...

ABBVIE'S INVESTIGATIONAL CHRONIC HEPATITIS C TREATMENT GRANTED PRIORITY REVIEW IN JAPAN

- ABBVIE'S INVESTIGATIONAL, INTERFERON AND RIBAVIRIN-FREE TREATMENT IN JAPAN CONSISTS OF A 12-WEEK, TWO DIRECT-ACTING ANTIVIRAL, FIXED-DOSED COMBINATION OF PARITAPREVIR/RITONAVIR WITH OMBITASVIR,...

VIVUS Files Lawsuit Against Teva for Infringement of Qsymia Patents

MOUNTAIN VIEW, CA--(Marketwired - April 15, 2015) - VIVUS, Inc. (NASDAQ: VVUS), a biopharmaceutical company commercializing and developing innovative, next-generation therapies to address unmet needs...

Pacira Receives Subpoena from the U.S. Department of Justice

PARSIPPANY, N.J.--(BUSINESS WIRE)--Apr. 16, 2015-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that it received a subpoena from the U.S. Department of Justice, U.S. Attorney's Office...

FDA Approves Corlanor® (ivabradine) To Reduce The Risk Of Hospitalization For Worsening Heart Failure In Patients With Chronic Heart Failure

Corlanor is the First New Chronic Heart Failure Medicine Approved by the FDA in Nearly a Decade

THOUSAND OAKS, Calif.,

Pfizer Announces PALOMA-3 Trial For IBRANCE® (Palbociclib) Stopped Early Due To Efficacy Seen In Patients With HR+, HER2- Metastatic Breast Cancer Whose Disease Has Progressed Following Endocrine Therapy

Pfizer Announces PALOMA-3 Trial For IBRANCE® (Palbociclib) Stopped Early Due To Efficacy Seen In Patients With HR+, HER2- Metastatic Breast Cancer Whose Disease Has Progressed Following Endocrine...

Melanoma Treatment Market Value to More than Quadruple to $5.64 Billion by 2023, says GlobalData

LONDON, UK (GlobalData), 15 April 2015 - The global treatment market for melanoma will expand more than fourfold in value from $1.34 billion in 2013 to reach an estimated $5.64 billion by 2023,...

Data in The Lancet show Novartis drug Arzerra(R) plus chlorambucil improved median progression-free survival by 71% in CLL patients

Significant improvement in PFS seen with Arzerra plus chlorambucil in previously untreated patients with CLL for whom fludarabine-based therapy was inappropriate Chronic lymphocytic leukemia (CLL)...

Abbott and Sekisui Collaborate to Offer Coagulation Testing for Laboratories Worldwide

- Coagulation tests measure a person's blood clotting ability, which can help doctors assess risks of excessive bleeding or developing clots

ABBOTT PARK, Ill.,

FDA ADVISORY COMMITTEE REVIEWS SAVOR OUTCOMES STUDY RESULTS FOR ONGLYZA(R) (SAXAGLIPTIN) AND KOMBIGLYZE(R) XR (SAXAGLIPTIN AND METFORMIN HCI EXTENDED-RELEASE)

AstraZeneca today announced that the US Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) voted 13 to 1 (1 abstained; 15 total votes) that the results...

Global Duchenne Muscular Dystrophy Treatment Market to See Spectacular Growth by 2019, says GlobalData

Global Duchenne Muscular Dystrophy Treatment Market to See Spectacular Growth by 2019, says GlobalData Duchenne Muscular Dystrophy (DMD) treatment market value to expand from approximately $8.2...